About IMMUNOVANT | DxMultiomics

IMMUNOVANT

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.

News Releases

Immunovant Awarded U.S. Patent For IMVT-1402

_↗ immunovant.com

Mar 12, 2024

IMMUNOVANT REPORTS POSITIVE INITIAL PHASE 2 RESULTS FOR BATOCLIMAB IN GRAVES’ DISEASE

_↗ immunovant.com

Dec 20, 2023

IMMUNOVANT ACHIEVES ALIGNMENT WITH FDA ON PLANS FOR PHASE 3 CLINICAL TRIALS OF BATOCLIMAB IN THYROID EYE DISEASE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2022

_↗ immunovant.com

Jun 8, 2022

IMMUNOVANT ANNOUNCES VOLUNTARY PAUSE IN CLINICAL DOSING OF IMVT-1401

_↗ immunovant.com

Feb 2, 2021

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.